Quarterly ResultAug 11, 2026, 05:14 PM
Sanara MedTech H1 Net Income $6K; Revenue Up 13.6% to $55.9M
AI Summary
Sanara MedTech Inc. reported a net income of $6,093 for the first half of 2026, a significant improvement from a net loss of $5.54 million in the prior year period. Total net revenue increased by 13.6% to $55.9 million for the six months ended June 30, 2026. The company's operating income also grew by 33.6% to $4.43 million for the half-year. This turnaround was aided by the discontinuation of the Tissue Health Plus (THP) segment, which previously incurred substantial losses, though the most recent quarter showed a loss from continuing operations.
Key Highlights
- Net income attributable to shareholders for H1 2026 was $6,093, compared to a net loss of $(5.54) million in H1 2025.
- Total net revenue for H1 2026 increased 13.6% to $55.9 million from $49.2 million in H1 2025.
- Operating income for H1 2026 rose 33.6% to $4.43 million, up from $3.31 million in H1 2025.
- Net loss from continuing operations for H1 2026 improved to $(13,457) from $(120,307) in H1 2025.
- Soft tissue repair product revenue for H1 2026 increased to $50.19 million from $43.19 million in H1 2025.
- Cash and cash equivalents decreased to $15.42 million as of June 30, 2026, from $16.58 million at December 31, 2025.
- The Tissue Health Plus (THP) segment was discontinued in Q3 2025, reducing losses from discontinued operations to $19,196 in H1 2026 from $(5.43) million in H1 2025.
Price Impact
More from SMTI